Browse Locations ... - Condition: Acute Noninfectious Posterior, Intermediate, or Pan Uveitis
Interventions: Drug: FTY720; Drug: Oral Corticosteroid
Sponsors: Novartis; Novartis Pharmaceuticals
Not yet recruiting - verified June 2013 - Condition: Idiopathic Pulmonary Fibrosis
Interventions: Drug: Simtuzumab (GS-6624); Drug: Placebo
Sponsors: Gilead Sciences; Gilead Sciences
Recruiting - verified June 2013 - Conditions: Advanced or Metastatic Hepatocellular Cancer; Advanced or Metastatic Ovarian Cancer; Metastatic Renal Cell Cancer; Advanced or Metastatic Gastric Carcinoma
Intervention: Drug: Tasquinimod
Sponsors: Ipsen; Ipsen
Recruiting - verified May 2013 - Condition: Rheumatoid Arthritis
Interventions: Drug: Placebo; Drug: Adalimumab; Drug: Baricitinib
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Chronic Cluster Headache
Intervention: Device: GammaCore
Sponsors: ElectroCore LLC; ElectroCore LLC
Recruiting - verified May 2013 - Condition: Psoriasis, Arthritic
Interventions: Drug: ixekizumab; Drug: Placebo; Drug: Adalimumab
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Psoriasis
Interventions: Drug: 80 mg ixekizumab Dosing Regimen; Drug: 50 mg etanercept; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Condition: Prostate Cancer
Interventions: Drug: cabazitaxel, prednisone, custirsen sodium; Drug: cabazitaxel, prednisone
Sponsors: OncoGenex Technologies; OncoGenex Technologies; Teva Pharmaceutical Industries
Recruiting - verified May 2013 - Condition: Breast Cancer
Interventions: Drug: Paclitaxel; Drug: BKM120 matching placebo; Drug: BKM120
Sponsors: Novartis; Novartis Pharmaceuticals
Recruiting - verified June 2013 - Condition: Pancreatic Cancer
Interventions: Drug: LY2495655; Drug: Gemcitabine; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Conditions: Systemic Sclerosis; Ulcers
Interventions: Drug: macitentan 3mg; Drug: macitentan 10mg; Drug: placebo
Sponsors: Actelion; Actelion
Recruiting - verified June 2013 - Condition: Peripheral T-cell Lymphoma
Intervention: Drug: Pralatrexate Injection
Sponsors: Spectrum Pharmaceuticals, Inc; Spectrum Pharmaceuticals, Inc
Recruiting - verified June 2013 - Condition: Endometrial Neoplasms
Interventions: Drug: PF-05212384; Drug: PF-05212384; Drug: PF-05212384
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Conditions: Cardiovascular Disease; Diabetes Mellitus, Type 2
Interventions: Drug: Dulaglutide; Drug: Placebo
Sponsors: Eli Lilly and Company; Eli Lilly and Company
Recruiting - verified June 2013 - Conditions: Left Ventricular Dysfunction; Heart Failure
Interventions: Device: CardioFit® System; Other: Standard of Care
Sponsors: BioControl Medical; BioControl Medical
Recruiting - verified May 2013 - Condition: Non Squamous Lung Cancer
Interventions: Drug: treatment; Drug: treatment
Sponsors: Pfizer; Pfizer
Recruiting - verified June 2013 - Condition: Pancreatic Cancer
Interventions: Drug: Notch signaling pathway inhibitor MK0752; Drug: gemcitabine hydrochloride; Other: imaging biomarker analysis; Other: laboratory biomarker analysis; Other: pharmacological study; Radiation: fludeoxyglucose F 18
Sponsors: Cancer Research UK; Cancer Research UK
Recruiting - verified May 2013 - Conditions: Influenza; (Influenza A and Subtypes Such as H3N2 and 2009 H1N1 or Influenza B)
Intervention:
Sponsors: University of Minnesota - Clinical and Translational Science Institute; University of Minnesota - Clinical and Translational Science Institute; National Institute of Allergy and Infectious Diseases (NIAID); National Institutes of Health (NIH)
Recruiting - verified June 2013 - Condition: Carcinoma, Ductal, Breast
Interventions: Radiation: Standard WB fractionation; Radiation: Shorter WB fractionation; Radiation: Standard WB fractionation+Boost; Radiation: Shorter WB fractionation + Boost
Sponsors: Trans-Tasman Radiation Oncology Group (TROG); Trans-Tasman Radiation Oncology Group (TROG); Breast International Group; NCIC Clinical Trials Group; ICORG- All Ireland Cooperative Oncology Research Group; Borstkanker Onderzoek Groep; International Breast Cancer Study Group; Scottish Cancer Trials Breast Group (SCTBG); European Organisation for Research and Treatment of Cancer - EORTC; Australian New Zealand Breast Cancer Trials Group
Recruiting - verified June 2013 - Condition: Oesophagogastric Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: cisplatin; Drug: Epirubicin; Procedure: adjuvant therapy; Procedure: conventional surgery; Procedure: neoadjuvant therapy; Drug: Lapatinib
Sponsors: Medical Research Council; Professor David Cunningham; Cancer Research UK
Recruiting - verified June 2013
 |
Paid Research Studies in Scotland |
Clinical Trial Locations 